Altimmune (ALT) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Altimmune (ALT) right now is Differentiated GLP-1/glucagon profile: Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. Product revenue is None (clinical-stage). If that keeps playing out, the setup is favourable; the risk to it is altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. No one can predict where ALT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Altimmune (ALT) higher?
Differentiated GLP-1/glucagon profile
Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. In the IMPACT MASH trial, the 1.8 mg dose showed about 7.5% weight loss alongside large reductions in liver fat.
MASH opportunity
The Phase 2b IMPACT trial hit key 48-week measures, with statistically significant improvements in noninvasive fibrosis markers versus placebo, supporting a planned Phase 3. MASH is a large, newly addressable market with few approved therapies.
Large obesity market
The GLP-1 obesity market is enormous and still expanding, so even a modest share for a differentiated entrant could be valuable. Pemvidutide targets both obesity and MASH, giving Altimmune two shots on goal from one molecule.
Funded for near-term milestones
Altimmune reported about $535 million in cash, equivalents, and short-term investments in Q1 2026, a substantial runway for a company its size that supports advancing pemvidutide toward Phase 3.
What could weigh on ALT?
Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders.
How to think about a ALT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ALT guide and whether ALT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ALT outlook
The bottom line: what is driving Altimmune (ALT) is Differentiated GLP-1/glucagon profile, with product revenue at None (clinical-stage). If that keeps playing out the setup is favourable; the risk is altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. No one can predict the price, so treat any ALT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ALT with Walnut
Use Altimmune as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Altimmune (ALT)?
+
No one can reliably predict where ALT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Altimmune higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ALT higher?
+
The main growth drivers are Differentiated GLP-1/glucagon profile; MASH opportunity; Large obesity market. Whether they play out is the real question, not a guaranteed path.
What are the risks to ALT?
+
Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders.
Will ALT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Altimmune's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ALT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ALT "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.